RCEL Avita Medical, Inc. - Common Stock
Tentang Avita Medical, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.
Baca selengkapnya
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.
Company history
Originally named "Clinical Cell Culture" and listed on the ASX under the symbol "C3", the company restructured under the name "Avita Medical" in June 2008. In 2015, the company conducted a strategic divestment of its respiratory business, including the Breath-a-Tech and Funhaler products, to support focus on its regenerative products.
Avita Medical is traded both on the Australian stock market under the ticker symbol AVH and on the American OTC stock market under the ticker symbol AVMXY.
ReCell, spray-on skin
ReCell is a device that enables clinicians to treat wounds and skin defects using very small samples of the patient's own cells. The procedure is performed on site at bedside and takes approximately 25 minutes to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in EMEA countries, China, and Australia and is in Pivotal/PIII trials in the US for burns as a first indication and a Pilot/PII US study underway for scars.
February 12, 2018 AVITA Medical announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the United States with the ReCell Autologous Cell Harvesting Device under a FDA Compassionate Use Investigational Device Exemption (IDE) program. Under the expanded protocol, up to 88 patients with life-threatening injuries, including severe burns, may be treated with ReCell. This is the fifth expansion to the Compassionate Use protocol for ReCell approved by the FDA and expands by 20 the number of patients who may be treated. Eligible patients are those who have insufficient healthy skin available for standard skin grafting treatment of their injuries and whose treating physicians believe there to be no suitable alternative treatment.
In October 2017, Avita Medical started to raise a goal of $17 million in capital for the product. The company worked with the Biomedical Advanced Research and Development Authority (BARDA) to raise money toward commercializing the product on the U.S. market.
September 28, 2017 Avita Medical announced submission of U.S. FDA Premarket Approval (PMA) Application for the ReCell device for treatment of burn injuries. The PMA submission includes clinical data from the two U.S. randomized, controlled trials with combined enrollment of 131 patients at twelve leading burn centers across the United States. The later trial demonstrated over 30% reduction in donor skin harvesting while achieving comparable near-term healing and long-term scar outcomes for treatment of third-degree burn injuries. Results from the earlier trial demonstrate a 97.5% reduction in donor skin harvested for treatment of second-degree burn injuries. The submission also includes a review of 55 cases of compassionate use of ReCell for extensive burn injuries.
September 21, 2017 Avita Medical announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes funding for key clinical and health economics research in U.S. pediatric burn care and extends Avita's Project Bioshield contract through to September 2022. Avita Medical has had a strong relationship with BARDA since the execution of a five-year contract in September 2015. Under the base contract BARDA made an initial investment of US$16.9 million to support Avita's ongoing U.S. clinical regulatory program towards FDA Premarket Approval (PMA), and to procure 5,000-plus ReCell devices. The contract also allowed BARDA to exercise future options to support additional clinical trials, and provide surge capacity for up to another 20,000 ReCell devices. Supplemental funding worth up to US$7.96 million was also provided to Avita under the contract in June 2016, to provide further operational support to Avita's PMA preparation and Compassionate Use program.
On September 20, 2018, Avita Medical's ReCell wound care device received FDA PMA approval.
US Government grant
In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.
Necrotizing fasciitis
In 2018 a burn center in Phoenix, Arizona held a press conference to discuss the ongoing results of using ReCell to treat a woman with flesh-eating bacteria also known as necrotizing fasciitis.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
RCEL Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
RCEL Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
RCEL Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
- Beli Kuat 2 20,0%
- Beli 5 50,0%
- Tahan 3 30,0%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
3 analis · 2026-08-13Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $-0.25 | $-0.29 | 0.04% |
| 31 Maret 2026 | $-0.35 | $-0.29 | -0.06% |
| 31 Des. 2025 | $-0.38 | $-0.34 | -0.04% |
| 30 Sep. 2025 | $-0.46 | $-0.29 | -0.17% |
| 30 Juni 2025 | $-0.38 | $-0.25 | -0.13% |
| 31 Maret 2025 | $-0.53 | $-0.39 | -0.14% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| CNXU | — | — | — | — | — | — |
| GLSI | $300M | -14.7 | — | — | -2159.7% | — |
| PYXS | $72M | -0.9 | -14.2% | -574.5% | -112.9% | — |
| TARA | $286M | -4.0 | — | — | -33.7% | — |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
| ALEC | $172M | -1.1 | -79.1% | -679.2% | -280.7% | — |
| EBS | $644M | 13.3 | -28.8% | 7.1% | 9.9% | — |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72M | $64M | $50M | $34M | · | $14M | $5M | |
| Cost of Revenue | $13M | $9M | $8M | $6M | · | $3M | $1M | |
| Gross Profit | $59M | $55M | $42M | $28M | · | $11M | $4M | |
| R&D Expense | $21M | $20M | $21M | $14M | · | $9M | $8M | |
| SG&A Expense | $27M | $33M | $28M | $23M | · | $33M | $15M | |
| Operating Expenses | $101M | $112M | $86M | $59M | · | $58M | $36M | |
| Operating Income | $-43M | $-57M | $-43M | $-28M | · | $-43M | $-26M | |
| Interest Expense | $5M | $5M | $1M | $16.0K | · | $33.0K | $27.0K | |
| Other Non-op | $-1M | $163.0K | $8M | $892.0K | · | · | · | |
| Pretax Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| Income Tax | $11.0K | $54.0K | $66.0K | $36.0K | · | $4.0K | $-121.0K | |
| Net Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| EPS (Basic) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| EPS (Diluted) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| Shares (Basic) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| Shares (Diluted) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| EBITDA | $-40M | $-55M | $-42M | $-27M | · | · | · |
Neraca 26
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $14M | $22M | $18M | $56M | $74M | $20M | |
| Short-term Investments | $8M | $22M | $67M | $61M | $30M | · | · | |
| Receivables | $9M | $12M | $8M | $4M | $3M | $2M | $1M | |
| Inventory | $7M | $7M | $6M | $2M | $2M | $1M | $742.0K | |
| Prepaid Expense | $1M | $2M | $2M | $2M | $1M | $990.0K | $1M | |
| Other Current Assets | · | · | $18.0K | $127.0K | $15.0K | $75.0K | $125.0K | |
| Current Assets | $35M | $57M | $104M | $87M | $92M | $78M | $24M | |
| PP&E (Net) | $9M | $10M | $2M | $1M | $1M | $1M | $1M | |
| Accum. Depreciation | $5M | $3M | $2M | $2M | $2M | $881.0K | $667.0K | |
| Intangibles | $6M | $6M | $487.0K | $465.0K | $443.0K | $364.0K | $225.0K | |
| Other Non-current Assets | $612.0K | $546.0K | $355.0K | $122.0K | $638.0K | $1.0K | $125.0K | |
| Total Assets | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Accounts Payable | $9M | $6M | $4M | $3M | $3M | $4M | $2M | |
| Current Liabilities | $63M | $20M | $13M | $11M | $9M | $8M | $4M | |
| Capital Leases | $2M | $3M | $2M | $306.0K | $918.0K | $2M | · | |
| Other Non-current Liabilities | · | · | · | · | $113.0K | $0 | $42.0K | |
| Total Liabilities | $73M | $75M | $62M | $13M | $11M | $10M | $5M | |
| Long-term Debt | $43M | $42M | · | · | · | · | · | |
| Total Debt | $43M | $42M | $40M | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $394M | $368M | $350M | $340M | $332M | $259M | $165M | |
| Retained Earnings | $-408M | $-360M | $-298M | $-263M | $-236M | $-195M | $-153M | |
| AOCI | $-1M | $-2M | $-2M | $8M | $8M | $8M | $8M | |
| Stockholders' Equity | $-17M | $4M | $49M | $85M | $105M | $72M | $21M | |
| Liabilities + Equity | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Shares Outstanding | 30,571,662 | 26,354,042 | 25,682,078 | 25,208,436 | 24,925,743 | 21,467,912 | 18,712,996 |
Arus Kas 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $1M | $632.0K | $568.0K | · | $465.0K | $269.0K | |
| Stock-based Comp | $10M | $13M | $8M | $7M | · | $16M | $2M | |
| Amort. of Intangibles | $600.0K | $93.0K | $35.0K | $58.0K | · | $119.0K | $0 | |
| Other Non-cash | $6M | $-2M | $-12M | $9.0K | · | · | · | |
| Operating Cash Flow | $-31M | $-49M | $-38M | $-19M | · | $-23M | $-19M | |
| CapEx | $1M | $9M | $1M | $452.0K | · | $590.0K | $1M | |
| Investing Cash Flow | $12M | $37M | $2M | $-19M | · | $-847.0K | $-1M | |
| Debt Issued | · | · | $39M | · | · | · | · | |
| Net Debt Issued | · | · | $39M | · | · | · | · | |
| Stock Issued | $15M | · | · | · | · | $82M | $32M | |
| Net Stock Activity | $15M | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $4M | $40M | $900.0K | · | $77M | $30M | |
| Net Change in Cash | $-4M | $-8M | $4M | $-38M | · | $53M | $9M | |
| Taxes Paid | $15.0K | $41.0K | $44.0K | $17.0K | · | · | · | |
| Free Cash Flow | $-32M | $-58M | $-39M | $-20M | · | · | · | |
| Levered FCF | $-37M | $-63M | $-41M | $-20M | · | · | · |
Profitabilitas 8
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.1% | 85.9% | 84.5% | 82.5% | · | · | · | |
| Operating Margin | -59.4% | -88.1% | -85.1% | -79.9% | · | · | · | |
| Net Margin | -67.8% | -96.3% | -70.6% | -77.5% | · | · | · | |
| Pretax Margin | -67.8% | -96.2% | -70.4% | -77.4% | · | · | · | |
| EBITDA Margin | -56.1% | -86.3% | -83.8% | -78.3% | · | · | · | |
| ROA | -71.4% | -64.6% | -33.7% | -24.9% | · | · | · | |
| ROE | 328.9% | -739.5% | -63.2% | -30.9% | · | · | · | |
| ROIC | -161.5% | -121.2% | -48.1% | -32.5% | · | · | · |
Likuiditas & Solvabilitas 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | 2.8 | 7.9 | 8.2 | · | · | · | |
| Quick Ratio | 0.4 | 2.4 | 7.3 | 7.7 | · | · | · | |
| Debt / Equity | -2.6 | 9.4 | 0.8 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 9.4 | 0.8 | · | · | · | · | |
| Interest Coverage | -8.5 | -10.6 | -37.3 | -1719.1 | · | · | · |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 0.7 | 0.5 | 0.3 | · | · | · | |
| Inventory Turnover | 1.8 | 1.4 | 2.0 | 2.8 | · | · | · | |
| Receivables Turnover | 6.9 | 6.6 | 9.0 | 10.4 | · | · | · |
Tingkat Pertumbuhan 2
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.5% | 28.1% | 45.7% | · | · | · | · | |
| Revenue CAGR 3Y | 27.7% | · | · | · | · | · | · |
Valuasi (TTM) 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $72M | $64M | $50M | $34M | · | $14M | · | |
| Net Income TTM | $-49M | $-62M | $-35M | $-27M | · | $-42M | · | |
| Market Cap | $105M | $337M | $352M | $166M | · | · | · | |
| Enterprise Value | $130M | $344M | $303M | · | · | · | · | |
| P/E | -2.0 | -5.4 | -9.8 | 6.2 | · | 14.8 | · | |
| P/S | 1.5 | 5.3 | 7.0 | 4.8 | · | · | · | |
| P/B | -6.3 | 75.0 | 7.2 | 2.0 | · | · | · | |
| P / Tangible Book | · | · | 7.3 | 2.0 | · | 9.1 | · | |
| P / Cash Flow | -3.4 | -6.9 | -9.3 | -8.7 | · | · | · | |
| P / FCF | -3.3 | -5.8 | -8.9 | -8.5 | · | · | · | |
| EV / EBITDA | -3.2 | -6.2 | -7.2 | · | · | · | · | |
| EV / FCF | -4.0 | -5.9 | -7.7 | · | · | · | · | |
| EV / Revenue | 1.8 | 5.3 | 6.0 | · | · | · | · | |
| Earnings Yield | -50.4% | -18.7% | -10.2% | 16.2% | · | 6.8% | · |
Laporan Laba Rugi 17
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22M | $19M | $18M | $17M | $18M | $19M | $18M | $20M | $15M | $11M | $14M | $14M | $12M | $11M | $9M | $9M | |
| Cost of Revenue | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | |
| Gross Profit | $18M | $16M | $14M | $14M | $15M | $16M | $16M | $16M | $13M | $10M | $12M | $12M | $10M | $9M | $8M | $8M | |
| R&D Expense | $5M | $6M | $6M | $4M | $5M | $6M | $5M | $5M | $5M | $5M | $7M | $4M | $5M | $5M | $3M | $4M | |
| SG&A Expense | $6M | $6M | $7M | $7M | $7M | $6M | $7M | $10M | $8M | $9M | $8M | $6M | $6M | $8M | $5M | $5M | |
| Operating Expenses | $25M | $25M | $25M | $23M | $26M | $28M | $26M | $30M | $29M | $27M | $25M | $21M | $21M | $19M | $15M | $14M | |
| Operating Income | $-7M | $-9M | $-10M | $-9M | $-11M | $-12M | $-10M | $-14M | $-16M | $-17M | $-12M | $-9M | $-11M | $-10M | $-6M | $-6M | |
| Interest Expense | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $10.0K | $7.0K | $4.0K | $-3.0K | $6.0K | |
| Other Non-op | $688.0K | $-395.0K | $20.0K | $-3M | $2M | $-791.0K | $-314.0K | $-1M | $2M | $-66.0K | $6M | $615.0K | $801.0K | $725.0K | · | · | |
| Pretax Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| Income Tax | $33.0K | $-11.0K | $-16.0K | $15.0K | $4.0K | $8.0K | $19.0K | $-28.0K | $33.0K | $30.0K | $12.0K | $11.0K | $13.0K | $30.0K | $24.0K | $4.0K | |
| Net Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| EPS (Basic) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| EPS (Diluted) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| Shares (Basic) | 30,749,894 | 30,540,872 | -53,153,774 | 28,393,445 | 26,367,548 | 26,253,565 | -51,498,934 | 25,983,929 | 25,760,278 | 25,637,783 | -50,512,301 | 25,401,754 | 25,239,723 | 25,202,088 | -49,916,057 | 25,006,995 | |
| Shares (Diluted) | 30,749,894 | 30,540,872 | -53,153,774 | 28,393,445 | 26,367,548 | 26,253,565 | -51,498,934 | 25,983,929 | 25,760,278 | 25,637,783 | -50,512,301 | 25,401,754 | 25,239,723 | 25,202,088 | -49,916,057 | 25,006,995 | |
| EBITDA | $-7M | $-8M | · | $-9M | $-11M | $-11M | · | $-14M | $-16M | $-17M | · | $-9M | $-11M | $-10M | · | $-6M |
Neraca 25
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $8M | $10M | $15M | $12M | $15M | $14M | $19M | $17M | $17M | $22M | $51M | $37M | $28M | $18M | $24M | |
| Short-term Investments | $2M | $6M | $8M | $8M | $3M | $11M | $22M | $26M | $37M | $51M | $67M | $9M | $29M | $45M | $61M | $61M | |
| Receivables | $10M | $10M | $9M | $9M | $11M | $12M | $12M | $10M | $9M | $7M | $8M | $6M | $6M | $5M | $4M | $4M | |
| Inventory | $5M | $6M | $7M | $7M | $8M | $8M | $7M | $6M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $3M | $2M | $1M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $8.0K | $135.0K | · | $26.0K | $525.0K | $29.0K | $127.0K | $17.0K | |
| Current Assets | $28M | $32M | $35M | $41M | $36M | $48M | $57M | $64M | $73M | $86M | $104M | $74M | $77M | $83M | $87M | $92M | |
| PP&E (Net) | $8M | $8M | $9M | $10M | $10M | $10M | $10M | $9M | $7M | $4M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Accum. Depreciation | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Intangibles | $5M | $5M | $6M | $5M | $5M | $5M | $6M | $590.0K | $545.0K | $542.0K | $487.0K | $459.0K | $456.0K | $461.0K | $465.0K | $449.0K | |
| Other Non-current Assets | $593.0K | $534.0K | $612.0K | $1M | $839.0K | $287.0K | $546.0K | $546.0K | $473.0K | $401.0K | $355.0K | $236.0K | $285.0K | $230.0K | $122.0K | $548.0K | |
| Total Assets | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Accounts Payable | $6M | $7M | $9M | $8M | $7M | $9M | $6M | $4M | $4M | $4M | $4M | $3M | $4M | $4M | $3M | $3M | |
| Current Liabilities | $69M | $67M | $63M | $62M | $63M | $23M | $20M | $17M | $14M | $12M | $13M | $12M | $14M | $11M | $11M | $10M | |
| Capital Leases | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | $1M | $306.0K | $405.0K | |
| Total Liabilities | $76M | $75M | $73M | $70M | $71M | $74M | $75M | $69M | $64M | $64M | $62M | $17M | $16M | $14M | $13M | $12M | |
| Long-term Debt | · | · | $43M | $42M | · | · | $42M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $47M | $46M | · | $42M | $42M | $41M | · | $43M | $41M | $41M | · | · | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $400M | $396M | $394M | $393M | $374M | $371M | $368M | $364M | $359M | $353M | $350M | $347M | $344M | $342M | $340M | $338M | |
| Retained Earnings | $-427M | $-419M | $-408M | $-397M | $-384M | $-374M | $-360M | $-348M | $-332M | $-317M | $-298M | $-291M | $-282M | $-272M | $-263M | $-257M | |
| AOCI | $-82.0K | $648.0K | $-1M | $-1M | $-2M | $-413.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $8M | $8M | $8M | $8M | $7M | |
| Stockholders' Equity | $-28M | $-23M | $-17M | $-7M | $-13M | $-5M | $4M | $12M | $24M | $33M | $49M | $63M | $69M | $78M | $85M | $88M | |
| Liabilities + Equity | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Shares Outstanding | 30,926,847 | 30,776,689 | 30,571,662 | 30,493,111 | 26,613,678 | 26,434,658 | 26,354,042 | 26,217,629 | 25,949,906 | 25,789,051 | 25,682,078 | 25,550,694 | 25,447,615 | 25,327,761 | 25,208,436 | 25,030,902 |
Arus Kas 13
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $605.0K | $627.0K | $700.0K | $574.0K | $552.0K | $521.0K | $409.0K | $310.0K | $204.0K | $203.0K | $187.0K | $164.0K | $146.0K | $135.0K | $130.0K | $138.0K | |
| Stock-based Comp | $2M | $1M | $1M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $2M | $2M | $1M | $3M | $1M | $1M | |
| Amort. of Intangibles | $196.0K | $204.0K | $160.0K | $153.0K | $152.0K | $135.0K | $36.0K | $23.0K | $17.0K | $17.0K | $9.0K | $9.0K | $8.0K | $9.0K | $8.0K | $8.0K | |
| Other Non-cash | · | $-1M | · | · | · | $335.0K | · | · | · | $-5M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-3M | $-10M | $-5M | $-5M | $-10M | $-10M | $-8M | $-7M | $-13M | $-21M | $-11M | $-9M | $-9M | $-9M | $-3M | $-3M | |
| CapEx | $108.0K | $19.0K | $-674.0K | $934.0K | $524.0K | $221.0K | $2M | $4M | $3M | $1M | $296.0K | $502.0K | $299.0K | $284.0K | $70.0K | $104.0K | |
| Investing Cash Flow | $4M | $2M | $11.0K | $-5M | $7M | $11M | $2M | $7M | $12M | $15M | $-57M | $22M | $18M | $19M | $-3M | $-8M | |
| Stock Issued | · | · | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $437.0K | $6M | $248.0K | $14M | $559.0K | $363.0K | $1M | $1M | $849.0K | $631.0K | $39M | $600.0K | $171.0K | $171.0K | $899.0K | $0 | |
| Net Change in Cash | $830.0K | $-2M | $-5M | $3M | $-3M | $820.0K | $-5M | $1M | $501.0K | $-5M | $-29M | $13M | $9M | $10M | $-6M | $-11M | |
| Taxes Paid | · | · | · | · | · | · | $20.0K | $2.0K | $19.0K | $17.0K | $0 | $0 | $44.0K | $9 | $0 | $0 | |
| Free Cash Flow | · | $-10M | · | · | · | $-11M | · | · | · | $-22M | · | · | · | $-9M | · | · | |
| Levered FCF | · | $-12M | · | · | · | $-12M | · | · | · | $-23M | · | · | · | $-9M | · | · |
Profitabilitas 8
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 81.7% | · | 81.3% | 81.2% | 84.7% | · | 83.7% | 86.1% | 86.4% | · | 84.5% | 81.2% | 84.2% | · | 83.2% | |
| Operating Margin | -31.6% | -45.7% | · | -53.6% | -60.5% | -63.9% | · | -70.6% | -102.8% | -155.0% | · | -68.2% | -95.0% | -93.9% | · | -63.2% | |
| Net Margin | -35.3% | -55.1% | · | -77.3% | -53.9% | -74.9% | · | -82.9% | -101.3% | -168.0% | · | -63.8% | -88.3% | -87.4% | · | -61.5% | |
| Pretax Margin | -35.2% | -55.2% | · | -77.2% | -53.8% | -74.8% | · | -83.0% | -101.1% | -167.8% | · | -63.8% | -88.2% | -87.1% | · | -61.4% | |
| EBITDA Margin | -31.6% | -42.5% | · | -53.6% | -60.5% | -61.1% | · | -70.6% | -102.8% | -153.1% | · | -68.2% | -95.0% | -92.7% | · | -63.2% | |
| ROA | -14.5% | -17.5% | · | -18.2% | -13.6% | -16.6% | · | -20.0% | -17.7% | -19.6% | · | -9.6% | -11.0% | -9.3% | · | -4.9% | |
| ROE | 37.6% | 76.5% | · | -474.3% | -180.0% | -99.0% | · | -43.1% | -33.3% | -33.9% | · | -11.5% | -12.9% | -10.5% | · | -5.4% | |
| ROIC | -36.6% | -38.3% | · | -25.6% | -38.0% | -32.1% | · | -25.2% | -24.1% | -23.3% | · | -14.8% | -16.3% | -12.8% | · | -6.5% |
Likuiditas & Solvabilitas 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.5 | · | 0.7 | 0.6 | 2.1 | · | 3.7 | 5.3 | 7.2 | · | 6.2 | 5.6 | 7.2 | · | 9.6 | |
| Quick Ratio | 0.3 | 0.4 | · | 0.5 | 0.4 | 1.6 | · | 3.2 | 4.6 | 6.3 | · | 5.6 | 5.2 | 6.8 | · | 9.2 | |
| Debt / Equity | -1.7 | -2.0 | · | -6.4 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| LT Debt / Equity | · | · | · | 0.0 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Interest Coverage | -4.7 | -6.2 | · | -7.2 | -8.9 | -9.6 | · | -10.2 | -11.6 | -12.7 | · | -930.6 | -1595.0 | -2477.8 | · | -958.0 |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.2 | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.6 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.9 | 0.7 | · | 0.8 | |
| Receivables Turnover | 2.0 | 1.8 | · | 1.8 | 1.8 | 1.9 | · | 2.4 | 2.1 | 1.9 | · | 2.9 | 2.4 | 2.6 | · | 3.1 |
Valuasi (TTM) 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $76M | $73M | · | $74M | $72M | $64M | · | $59M | $52M | $47M | · | $45M | $40M | $36M | · | $32M | |
| Net Income TTM | $-41M | $-48M | · | $-53M | $-55M | $-64M | · | $-59M | $-53M | $-47M | · | $-34M | $-31M | $-31M | · | $-27M | |
| Market Cap | $128M | $114M | · | $156M | $141M | $215M | · | $281M | $206M | $413M | · | $373M | $433M | $354M | · | $132M | |
| Enterprise Value | $163M | $146M | · | $175M | $167M | $231M | · | $279M | $192M | $387M | · | · | · | · | · | · | |
| P/E | -2.9 | -2.2 | · | -2.6 | -2.5 | -3.3 | · | -4.7 | -3.8 | -8.7 | · | -16.2 | -54.9 | 29.1 | · | 4.8 | |
| P/S | 1.7 | 1.6 | · | 2.1 | 2.0 | 3.3 | · | 4.7 | 4.0 | 8.8 | · | 8.3 | 10.9 | 10.0 | · | 4.1 | |
| P/B | -4.6 | -4.9 | · | -23.4 | -10.9 | -47.1 | · | 23.0 | 8.6 | 12.7 | · | 5.9 | 6.3 | 4.6 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | 24.2 | 8.8 | 12.9 | · | 6.0 | 6.3 | 4.6 | · | 1.5 | |
| P / Cash Flow | · | -11.3 | · | · | · | -20.9 | · | · | · | -19.8 | · | · | · | -39.0 | · | · | |
| P / FCF | · | -11.3 | · | · | · | -20.4 | · | · | · | -18.8 | · | · | · | -37.8 | · | · | |
| EV / EBITDA | -23.8 | -17.8 | · | -19.1 | -15.0 | -20.4 | · | -20.2 | -12.3 | -22.7 | · | · | · | · | · | · | |
| EV / FCF | · | -14.4 | · | · | · | -21.9 | · | · | · | -17.6 | · | · | · | · | · | · | |
| EV / Revenue | 2.1 | 2.0 | · | 2.4 | 2.3 | 3.6 | · | 4.7 | 3.7 | 8.2 | · | · | · | · | · | · | |
| Earnings Yield | -34.9% | -46.5% | · | -38.9% | -40.3% | -30.5% | · | -21.4% | -26.3% | -11.5% | · | -6.2% | -1.8% | 3.4% | · | 20.7% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $72M | $64M | $50M | $34M | — |
| Margin Kotor % | 82.1% | 85.9% | 84.5% | 82.5% | — |
| Margin Operasi % | -59.4% | -88.1% | -85.1% | -79.9% | — |
| Laba Bersih | $-49M | $-62M | $-35M | $-27M | — |
| EPS Dilusian | $-1.74 | $-2.39 | $-1.40 | $1.07 | — |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | -2.6 | 9.4 | 0.8 | — | — |
| Rasio Lancar | 0.6 | 2.8 | 7.9 | 8.2 | — |
| Rasio Cepat | 0.4 | 2.4 | 7.3 | 7.7 | — |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-32M | $-58M | $-39M | $-20M | — |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 81 pengaju · $18.7M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 26 (0 vs Kuartal sebelumnya) | 23 (+10 vs Kuartal sebelumnya) | 26 (+5 vs Kuartal sebelumnya) | 17 (+3 vs Kuartal sebelumnya) | -39.7M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5.509.065 | 1.333.914 | 29,41% | Saham |
| VANGUARD GROUP INC | $4.326.172 | 1.253.963 | 23,10% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $1.124.496 | 272.127 | 6,00% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $753.320 | 182.402 | 4,02% | Saham |
| NewEdge Advisors, LLC | $615.085 | 148.931 | 3,28% | Saham |
| MACQUARIE GROUP LTD | $595.395 | 144.164 | 3,18% | Saham |
| STATE STREET CORP | $532.675 | 128.977 | 2,84% | Saham |
| Quantinno Capital Management LP | $434.674 | 105.248 | 2,32% | Saham |
| Divisadero Street Capital Management, LP | $413.000 | 100.000 | 2,20% | Saham |
| GOLDMAN SACHS GROUP INC | $316.924 | 76.737 | 1,69% | Saham |
| NORTHERN TRUST CORP | $284.090 | 68.787 | 1,52% | Saham |
| Qube Research & Technologies Ltd | $263.428 | 63.784 | 1,41% | Saham |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $250.881 | 60.746 | 1,34% | Saham |
| XTX Topco Ltd | $236.075 | 57.161 | 1,26% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $222.847 | 53.958 | 1,19% | Saham |
| BANK OF AMERICA CORP /DE/ | $213.384 | 51.667 | 1,14% | Saham |
| MARSHALL WACE, LLP | $203.304 | 49.226 | 1,09% | Saham |
| Nuveen Asset Management, LLC | $159.002 | 12.422 | 0,85% | Saham |
| FMR LLC | $134.287 | 32.515 | 0,72% | Saham |
| IEQ CAPITAL, LLC | $133.812 | 32.400 | 0,71% | Saham |
| THOMPSON DAVIS & CO., INC. | $128.402 | 31.090 | 0,69% | Saham |
| Jain Global LLC | $127.101 | 30.775 | 0,68% | Saham |
| AMERIPRISE FINANCIAL INC | $117.696 | 28.498 | 0,63% | Saham |
| Russell Investments Group, Ltd. | $115.863 | 28.054 | 0,62% | Saham |
| IHT Wealth Management, LLC | $101.599 | 24.600 | 0,54% | Saham |
| Squarepoint Ops LLC | $95.035 | 23.011 | 0,51% | Saham |
| R Squared Ltd | $94.506 | 22.883 | 0,50% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92.512 | 22.400 | 0,49% | Opsi beli |
| BlackRock, Inc. | $90.174 | 21.834 | 0,48% | Saham |
| CITADEL ADVISORS LLC | $87.746 | 21.246 | 0,47% | Saham |
| Mariner, LLC | $81.090 | 19.634 | 0,43% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65.254 | 15.800 | 0,35% | Opsi jual |
| CITADEL ADVISORS LLC | $65.254 | 15.800 | 0,35% | Opsi jual |
| Abel Hall, LLC | $65.167 | 15.779 | 0,35% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.734 | 15.674 | 0,35% | Saham |
| MILLENNIUM MANAGEMENT LLC | $63.722 | 15.429 | 0,34% | Saham |
| GABELLI FUNDS LLC | $61.950 | 15.000 | 0,33% | Saham |
| nVerses Capital, LLC | $56.448 | 13.668 | 0,30% | Saham |
| China Universal Asset Management Co., Ltd. | $51.625 | 12.500 | 0,28% | Saham |
| Quadrature Capital Ltd | $48.854 | 11.829 | 0,26% | Saham |
| MERCER GLOBAL ADVISORS INC /ADV | $48.073 | 11.640 | 0,26% | Saham |
| Cerity Partners LLC | $41.259 | 9.990 | 0,22% | Saham |
| Vanguard Global Advisers, LLC | $40.201 | 9.734 | 0,21% | Saham |
| AlphaQuest LLC | $32.354 | 9.378 | 0,17% | Saham |
| Arax Advisory Partners | $29.542 | 7.153 | 0,16% | Saham |
| AQR CAPITAL MANAGEMENT LLC | $28.179 | 6.823 | 0,15% | Saham |
| RHUMBLINE ADVISERS | $27.302 | 6.611 | 0,15% | Saham |
| CWM, LLC | $19.632 | 5.306 | 0,10% | Saham |
| JONES FINANCIAL COMPANIES LLLP | $17.083 | 4.303 | 0,09% | Saham |
| Tower Research Capital LLC (TRC) | $9.387 | 2.273 | 0,05% | Saham |
| WELLS FARGO & COMPANY/MN | $9.003 | 2.180 | 0,05% | Saham |
| Optiver Holding B.V. | $5.856 | 1.418 | 0,03% | Saham |
| Integrated Wealth Concepts LLC | $5.157 | 1.249 | 0,03% | Saham |
| PNC Financial Services Group, Inc. | $3.444 | 834 | 0,02% | Saham |
| OSAIC HOLDINGS, INC. | $2.601 | 630 | 0,01% | Saham |
| UBS Group AG | $2.172 | 526 | 0,01% | Saham |
| Allworth Financial LP | $2.070 | 501 | 0,01% | Saham |
| MORGAN STANLEY | $1.966 | 476 | 0,01% | Saham |
| Essential Partners LLC | $1.788 | 433 | 0,01% | Saham |
| IFP Advisors, Inc | $1.689 | 409 | 0,01% | Saham |
| SBI Securities Co., Ltd. | $1.218 | 295 | 0,01% | Saham |
| JPMORGAN CHASE & CO | $808 | 190 | 0,00% | Saham |
| GAMMA Investing LLC | $785 | 190 | 0,00% | Saham |
| True Wealth Design, LLC | $608 | 147 | 0,00% | Saham |
| ROTHSCHILD INVESTMENT LLC | $491 | 119 | 0,00% | Saham |
| NISA INVESTMENT ADVISORS, LLC | $384 | 93 | 0,00% | Saham |
| Fortitude Family Office, LLC | $285 | 69 | 0,00% | Saham |
| EverSource Wealth Advisors, LLC | $264 | 64 | 0,00% | Saham |
| Farther Finance Advisors, LLC | $260 | 62 | 0,00% | Saham |
| Caitong International Asset Management Co., Ltd | $194 | 47 | 0,00% | Saham |
| Parallel Advisors, LLC | $165 | 40 | 0,00% | Saham |
| SJS Investment Consulting Inc. | $141 | 34 | 0,00% | Saham |
| Virtu Financial LLC | $101 | 24.482 | 0,00% | Saham |
| Wealth Enhancement Trust Services, Inc. | $99 | 24 | 0,00% | Saham |
| HRT FINANCIAL LP | $42 | 10.179 | 0,00% | Saham |
| JPL Wealth Management, LLC | $25 | 6 | 0,00% | Saham |
| Clearstead Advisors, LLC | $13 | 3 | 0,00% | Saham |
| Sunbelt Securities, Inc. | $11 | 3 | 0,00% | Saham |
| BARCLAYS PLC | $4 | 1 | 0,00% | Saham |
| Capital Analysts, LLC | $3 | 652 | 0,00% | Saham |
| ROYAL BANK OF CANADA | $0 | 56 | 0,00% | Saham |
Orang dalam perusahaan 20 orang dalam · 11 pejabat · 11 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Cary Guy Vance | President and CEO | 29 Mei 2026 A | 40.771 | 0 | 0 | $0 |
| James Corbett | CEO | 21 Jan. 2025 A | 11.580 | 0 | 0 | $0 |
| David D O'Toole | CFO | 12 Juni 2026 A | 152.927 | 5 | 0 | $47.094 |
| Sean Ekins | Interim CFO | 6 Juni 2023 A | 5.000 | 0 | 0 | $0 |
| Michael Holder | Chief Financial Officer | 1 Juli 2022 A | 46.450 | 0 | 0 | $0 |
| David Mcintyre | Chief Financial Officer | 17 Juli 2020 P | 893 | 0 | 0 | $0 |
| Kathy M. Mcgee | Chief Operating Officer | 1 Juli 2022 A | 46.450 | 0 | 0 | $0 |
| Nicole Kelsey | Chief Legal Officer | 18 Feb. 2026 A | 98.390 | 0 | 0 | $0 |
| Donna Shiroma | General Counsel | 31 Mei 2024 A | 45.951 | 0 | 0 | $0 |
| Andrew Quick | Chief Technology Officer | 6 Juni 2023 A | 46.450 | 0 | 0 | $0 |
| Erin Liberto | Chief Commercial Officer | 1 Juli 2022 A | 46.450 | 0 | 0 | $0 |
| Joseph Fralin Woody | Direktur | 9 Juni 2026 P | 107.961 | 5 | 0 | $104.900 |
| Suzanne Crowe | Direktur | 3 Juni 2026 A | 69.148 | 0 | 0 | $0 |
| Michael E Tarnoff | Direktur | 3 Juni 2026 A | 48.464 | 0 | 0 | $0 |
| Robert Mcnamara | Direktur | 20 Jan. 2026 A | 108.985 | 2 | 0 | $95.000 |
| Jeremy Curnock Cook | Direktur | 20 Jan. 2026 A | 62.050 | 0 | 0 | $0 |
| Jan Stern Reed | Direktur | 20 Jan. 2026 A | 73.225 | 0 | 0 | $0 |
| Lou Panaccio | Direktur | 21 Jan. 2025 A | 56.428 | 0 | 0 | $0 |
| Michael S Perry | Direktur | 21 Nov. 2022 M | 229.543 | 0 | 0 | $0 |
| Louis Drapeau | Direktur | 22 Des. 2021 A | 4.689 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 10 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| IWC · iShares Trust | 0,03% | 108.036 SH | 8 Agu 2026 | Harian |
| GSSC · Goldman Sachs ETF Trust | 0,01% | 18.465 NS | 31 Mei 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 3.453 NS | 31 Mei 2026 | N-PORT |
| RSSL · Global X Funds | 0,00% | 5.475 NS | 30 April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,00% | 663 NS | 31 Mei 2026 | N-PORT |
| UWM · ProShares Trust | 0,00% | 517 NS | 31 Mei 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 521 NS | 31 Mei 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 13 NS | 31 Mei 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 341.039 SH | 8 Agu 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 958.401 SH | 8 Agu 2026 | Harian |